Allosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
List view / Grid view
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
Using saturation genome editing, researchers have created a map of disease-causing mutations for neurodevelopmental disorders and cancer.
Researchers have genetically profiled nearly 200,000 cells from lungs, mapping their precise locations in tissue to discover an unexpected new immune niche in our airways.
Victoria Rees and Ria Kakkad from Drug Target Review bring you the key takeaways from the ELRIG Drug Discovery 2022 event in London.
A recent genomic surveillance study has demonstrated the value of genomics to inform vaccine design and highlight the challenge posted by shapeshifting bacteria.
Two new papers from the Human Cell Atlas shed new light on the types and traits of immune cells that can be found in the human body, from developmental stages to adulthood.
Scientists have used genetic sequencing to demonstrate how the transmission of gut bacteria influences its evolution and functions, which could effect human health.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
The Atlas of Variant Effects Alliance will develop a map of human genetic variants to advance the understanding and treatment of disease.
Researchers have discovered that all childhood neuroblastomas come from sympathoblasts, making them a drug target to treat the condition.
A study has identified more than 200 genes that drive the progression of glioblastoma and which the researchers say present drug targets.
An international group of researchers has revealed that goblet and ciliated cells in the nose have high levels of the entry proteins for the SARS-CoV-2 coronavirus.
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.